Neuronal Histone Methyltransferase EZH2 Regulates Neuronal Morphogenesis, Synaptic Plasticity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Flexible Microfluidic System for Single-Cell Transcriptome Profiling
www.nature.com/scientificreports OPEN A fexible microfuidic system for single‑cell transcriptome profling elucidates phased transcriptional regulators of cell cycle Karen Davey1,7, Daniel Wong2,7, Filip Konopacki2, Eugene Kwa1, Tony Ly3, Heike Fiegler2 & Christopher R. Sibley 1,4,5,6* Single cell transcriptome profling has emerged as a breakthrough technology for the high‑resolution understanding of complex cellular systems. Here we report a fexible, cost‑efective and user‑ friendly droplet‑based microfuidics system, called the Nadia Instrument, that can allow 3′ mRNA capture of ~ 50,000 single cells or individual nuclei in a single run. The precise pressure‑based system demonstrates highly reproducible droplet size, low doublet rates and high mRNA capture efciencies that compare favorably in the feld. Moreover, when combined with the Nadia Innovate, the system can be transformed into an adaptable setup that enables use of diferent bufers and barcoded bead confgurations to facilitate diverse applications. Finally, by 3′ mRNA profling asynchronous human and mouse cells at diferent phases of the cell cycle, we demonstrate the system’s ability to readily distinguish distinct cell populations and infer underlying transcriptional regulatory networks. Notably this provided supportive evidence for multiple transcription factors that had little or no known link to the cell cycle (e.g. DRAP1, ZKSCAN1 and CEBPZ). In summary, the Nadia platform represents a promising and fexible technology for future transcriptomic studies, and other related applications, at cell resolution. Single cell transcriptome profling has recently emerged as a breakthrough technology for understanding how cellular heterogeneity contributes to complex biological systems. Indeed, cultured cells, microorganisms, biopsies, blood and other tissues can be rapidly profled for quantifcation of gene expression at cell resolution. -
Human Catechol O-Methyltransferase Genetic Variation
Molecular Psychiatry (2004) 9, 151–160 & 2004 Nature Publishing Group All rights reserved 1359-4184/04 $25.00 www.nature.com/mp ORIGINAL RESEARCH ARTICLE Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes AJ Shield1, BA Thomae1, BW Eckloff2, ED Wieben2 and RM Weinshilboum1 1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School, Mayo Clinic, Mayo Foundation, Rochester, MN, USA; 2Department of Biochemistry and Molecular Biology, Mayo Medical School, Mayo Clinic, Mayo Foundation, Rochester, MN, USA Catechol O-methyltransferase (COMT) plays an important role in the metabolism of catecholamines, catecholestrogens and catechol drugs. A common COMT G472A genetic polymorphism (Val108/158Met) that was identified previously is associated with decreased levels of enzyme activity and has been implicated as a possible risk factor for neuropsychiatric disease. We set out to ‘resequence’ the human COMT gene using DNA samples from 60 African-American and 60 Caucasian-American subjects. A total of 23 single nucleotide polymorphisms (SNPs), including a novel nonsynonymous cSNP present only in DNA from African-American subjects, and one insertion/deletion were observed. The wild type (WT) and two variant allozymes, Thr52 and Met108, were transiently expressed in COS-1 and HEK293 cells. There was no significant change in level of COMT activity for the Thr52 variant allozyme, but there was a 40% decrease in the level of activity in cells transfected with the Met108 construct. Apparent Km values of the WT and variant allozymes for the two reaction cosubstrates differed slightly, but significantly, for 3,4-dihydroxybenzoic acid but not for S-adenosyl-L-methionine. -
The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota. -
EZH2 in Normal Hematopoiesis and Hematological Malignancies
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 3 EZH2 in normal hematopoiesis and hematological malignancies Laurie Herviou2, Giacomo Cavalli2, Guillaume Cartron3,4, Bernard Klein1,2,3 and Jérôme Moreaux1,2,3 1 Department of Biological Hematology, CHU Montpellier, Montpellier, France 2 Institute of Human Genetics, CNRS UPR1142, Montpellier, France 3 University of Montpellier 1, UFR de Médecine, Montpellier, France 4 Department of Clinical Hematology, CHU Montpellier, Montpellier, France Correspondence to: Jérôme Moreaux, email: [email protected] Keywords: hematological malignancies, EZH2, Polycomb complex, therapeutic target Received: August 07, 2015 Accepted: October 14, 2015 Published: October 20, 2015 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the Polycomb repressive complex 2, inhibits gene expression through methylation on lysine 27 of histone H3. EZH2 regulates normal hematopoietic stem cell self-renewal and differentiation. EZH2 also controls normal B cell differentiation. EZH2 deregulation has been described in many cancer types including hematological malignancies. Specific small molecules have been recently developed to exploit the oncogenic addiction of tumor cells to EZH2. Their therapeutic potential is currently under evaluation. This review summarizes the roles of EZH2 in normal and pathologic hematological processes and recent advances in the development of EZH2 inhibitors for the personalized treatment of patients with hematological malignancies. PHYSIOLOGICAL FUNCTIONS OF EZH2 state through tri-methylation of lysine 27 on histone H3 (H3K27me3) [6]. -
Rabbit Anti-Human EZH2 Monoclonal Antibody, Clone 9I43M54 (CABT-L1296) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
Rabbit Anti-Human EZH2 monoclonal antibody, clone 9I43M54 (CABT-L1296) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Specificity This antibody is predicted to react with Monkey, Rat, Horse, Mouse Target EZH2 Immunogen Protein corresponding to human EZH2 (aa156-aa265) Isotype IgG Source/Host Rabbit Species Reactivity Human Clone 9I43M54 Purification Protein A Purified Conjugate Unconjugated Applications WB Format Liquid Concentration 0.5 mg/ml Buffer PBS, pH 7.4 Preservative 0.09% Sodium Azide Storage -20°C, Avoid Freeze/Thaw Cycles Warnings For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. BACKGROUND Introduction EZH2 was initially identified as a homolog of the drosophila Enhancer of Zeste through exon trap screening of chromosome 21. Both EZH2 and the related protein EZH1 can form complexes with the noncanonical Polycomb repressive complex-2 (PRC2) and maintain repressive chromatin, 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved but the PRC2-EZH1 complex mediates methylation of histone H3. Both EZH1 and EZH2 are thought to function in the maintenance of embryonic stem cell pluripotency and plasticity and have been shown to be essential for hair follicle homeostasis and wound repair. Overexpression of EZH2 has been reported as a marker for advanced and metastatic cancers. Keywords EZH2;enhancer of zeste homolog 2 (Drosophila);WVS;ENX1;EZH1;KMT6;WVS2;ENX- 1;EZH2b;KMT6A;histone-lysine N-methyltransferase EZH2;lysine N-methyltransferase 6 GENE INFORMATION Entrez Gene ID 2146 UniProt ID Q15910 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved. -
Generate Metabolic Map Poster
Authors: Pallavi Subhraveti Ron Caspi Peter Midford Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_003855395Cyc: Shewanella livingstonensis LMG 19866 Cellular Overview Connections between pathways are omitted for legibility. -
The Importance of Study Design Abundant Features in High
The importance of study design for detecting differentially abundant features in high -throughput experiments Luo Huaien 1* , Li Juntao 1*, C hia Kuan Hui Burton 1, Paul Robson 2, Niranjan Nagarajan 1# a b c d Supplementary Figure 1. Variability in performance across DATs with few repreplicates.licates. The subfigures depict precision-recall tradeoffs for DATs, under a range of experimexperimenentaltal conditions and with few replicates (2 in this case). The following parameters were used in EDDA for the sub figures: (a) PDA=30% and FC=Uniform[2,6] (b) as in subfigure (a) but with AP=HBR (c) PDA= [15% UP, 30% DOWN] and FC=Uniform[3,15] (d) PDA=[50% UP, 25% DOWN], FC=Normal[5,1.33] and SM=Full. Common parameters unless otherwise stated include AP=BP, EC=1000, ND=500 per entity, SM=NB and SV=0.5. a b c d Supplementary Figure 2 . Variability in performance across DATs with few data -points. Note that as in Supplementary Figure 1 , the performance of DATs varies widely merely by changing the number of replicates from 1 to 4 in sub figures (a)-(d) in a situation where the number data -points generated is limited (only 50 on average per entity). Results reported are based on data generated in EDDA with the following parameters (roughly mimicking a microbial RNA-seq application) : EC=1000, PDA=26%, FC=Uniform[3,7 ], AP=BP, SM=Full and SV=0.85. Supplementary Figure 3. Distribution of relative abundance in different empirically derived profiles. Note that both axes are plotted on a log-scale and that while BP does not have entities with relative abundance < 1e-5, the profile from Wu et al is more enriched for entities with relative abundance < 1e-5 than the HBR profile. -
Expanding the Structural Diversity of DNA Methyltransferase Inhibitors
pharmaceuticals Article Expanding the Structural Diversity of DNA Methyltransferase Inhibitors K. Eurídice Juárez-Mercado 1 , Fernando D. Prieto-Martínez 1 , Norberto Sánchez-Cruz 1 , Andrea Peña-Castillo 1, Diego Prada-Gracia 2 and José L. Medina-Franco 1,* 1 DIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, National Autonomous University of Mexico, Avenida Universidad 3000, Mexico City 04510, Mexico; [email protected] (K.E.J.-M.); [email protected] (F.D.P.-M.); [email protected] (N.S.-C.); [email protected] (A.P.-C.) 2 Research Unit on Computational Biology and Drug Design, Children’s Hospital of Mexico Federico Gomez, Mexico City 06720, Mexico; [email protected] * Correspondence: [email protected] Abstract: Inhibitors of DNA methyltransferases (DNMTs) are attractive compounds for epigenetic drug discovery. They are also chemical tools to understand the biochemistry of epigenetic processes. Herein, we report five distinct inhibitors of DNMT1 characterized in enzymatic inhibition assays that did not show activity with DNMT3B. It was concluded that the dietary component theaflavin is an inhibitor of DNMT1. Two additional novel inhibitors of DNMT1 are the approved drugs glyburide and panobinostat. The DNMT1 enzymatic inhibitory activity of panobinostat, a known pan inhibitor of histone deacetylases, agrees with experimental reports of its ability to reduce DNMT1 activity in liver cancer cell lines. Molecular docking of the active compounds with DNMT1, and re-scoring with the recently developed extended connectivity interaction features approach, led to an excellent agreement between the experimental IC50 values and docking scores. Citation: Juárez-Mercado, K.E.; Keywords: dietary component; epigenetics; enzyme inhibition; focused library; epi-informatics; Prieto-Martínez, F.D.; Sánchez-Cruz, multitarget epigenetic agent; natural products; chemoinformatics N.; Peña-Castillo, A.; Prada-Gracia, D.; Medina-Franco, J.L. -
Catechol-O-Methyltransferase Inhibitor, on the Motor Response to Acute Treatment with Levodopa in Patients with Parkinson's Disease
18616ournal ofNeurology, Neurosurgery, and Psychiatry 1994;57:186-189 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.57.2.186 on 1 February 1994. Downloaded from Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease Marcelo Merello, Andrew J Lees, Roy Webster, Michael Bovingdon, Ariel Gordin Abstract treatment.7-'0 The oral bioavailability of lev- Catechol-O-methyltransferase (COMT) odopa is low due to first pass metabolism inhibitors may be useful in the treatment which is at least partly due to the high activity of Parkinson's disease by improving the of COMT in the gut and liver." 12 The com- bioavailability of levodopa and by pro- bination of a peripheral COMT inhibitor longing its effects. Entacapone (OR-611), with levodopa/DCI therapy might therefore a novel COMT inhibitor, which does not produce a smoother and more prolonged cross the blood brain barrier, was motor response in patients with Parkinson's assessed in 12 patients with Parkinson's disease."3 14 As early as in 1971 Ericsson'5 disease and motor fluctuations in a reported beneficial effects with a COMT randomised, double-blind, cross-over, inhibitor with concomitant reduction in single dose study. The magnitude and levodopa-induced dyskinesias. More recently, duration of the therapeutic response to a a new generation of COMT inhibitors have single dose of 200 mg levodopa/50 mg been developed, which are much more potent carbidopa was evaluated after concomi- and specific."'3 1620 Fluorodopa positron tant placebo, or 200 or 800 mg enta- emission tomography (PET) studies in mon- capone. -
Mechanism of N-Methylation by the Trna M1g37 Methyltransferase Trm5
Thomas Jefferson University Jefferson Digital Commons Department of Biochemistry and Molecular Department of Biochemistry and Molecular Biology Faculty Papers Biology 12-1-2010 Mechanism of N-methylation by the tRNA m1G37 methyltransferase Trm5. Thomas Christian Thomas Jefferson University Georges Lahoud Thomas Jefferson University Cuiping Liu Thomas Jefferson University Katherine Hoffmann University of California at Santa Barbara Follow this and additional works at: https://jdc.jefferson.edu/bmpfp John J Perona Univ Persityart of of the California Biochemistr at Santay Commons Barbara, Medical Biochemistry Commons, and the Molecular Biology Commons SeeLet next us page know for additional how authors access to this document benefits ouy Recommended Citation Christian, Thomas; Lahoud, Georges; Liu, Cuiping; Hoffmann, Katherine; Perona, John J; and Hou, Ya-Ming, "Mechanism of N-methylation by the tRNA m1G37 methyltransferase Trm5." (2010). Department of Biochemistry and Molecular Biology Faculty Papers. Paper 26. https://jdc.jefferson.edu/bmpfp/26 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Biochemistry and Molecular Biology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. -
Arylamine N-Methyltransferase and Thiol Methyltransferase Activities in Cholestatic Rat Liver Induced by Common Bile Duct Ligation
EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 33, No. 1, 23-28, March 2001 Arylamine N-methyltransferase and thiol methyltransferase activities in cholestatic rat liver induced by common bile duct ligation You Hee Kim1,2 and Il Joo1 using tryptamine or 4-chlorothiophenol as substrates and S-Adenosyl-L-[methyl-3H]methionine as co-sub- 1 Department of Biochemistry, Keimyung University School of strate. The results indicate that although the Km val- Medicine, Taegu 700-712, Korea ues were about the same as the sham-operated 2 Corresponding author: Tel, +82-53-250-7462; control, the Vmax values of both enzymes increased Fax, +82-53-252-1605; E-mail, [email protected] significantly (Pú0.01 and 0.001, respectively). These results suggest that the biosynthesis of arylamine Accepted 2 March, 2001 N-methyltransferase and thiol methyltransferase have been induced in response to obstructive jaun- dice. Abstract Keywords: arylamine N-methyltransferase, cholestatic Methylation catalyzed by methyltransferases is a rat liver, enzyme induction, thiol methyltransferase major metabolic pathway for an inactivation of some catecholamines, niacinamide as well as aliphatic sulfhydryl drugs and toxic hydrogen sulfides. To investigate the effects of obstructive jaundice in an Introduction animal model, common bile duct ligation (CBDL) was performed in the rat and enzyme activities of S- Methylation is a major metabolic pathway for an inacti- adenosyl-L-methionine-dependent arylamine N- vation of some catecholamines, niacinamide as well as methyltransferase and thiol methyltransferase were aliphatic sulfhydryl drugs and toxic hydrogen sulfides examined in liver cell fractions and serum for a catalyzed by methyltransferases (N-methyltransferases period of 42 d after CBDL. -
Epigenetic-Mediated Apoptosis in Aggressive B-Cell Lymphomas
Epigenetic-mediated apoptosis in aggressive B-cell lymphomas Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Chidimma Agatha Akpa 2019 This dissertation was prepared at the Medical University, Berlin Institute of Pathology Department of Experimental Hematopathology under the supervision of Prof. Dr. Michael Hummel from January 2016 till November 2019 1st Reviewer: Prof. Dr. Michael Hummel 2nd Reviewer: Prof. Dr. Rupert Mutzel Date of defense: 16.03.2020 2 Directory Summary .................................................................................................................................... 7 Zusammenfassung ..................................................................................................................... 9 CHAPTER ONE ...................................................................................................................... 11 BACKGROUND .................................................................................................................. 11 1.1 Lymphomas .................................................................................................................... 11 1.1.1 Burkitt lymphoma (BL) ........................................................................................... 11 1.1.2 Diffuse large B-cell lymphoma (DLBCL) ............................................................... 12 1.2 Epigenetics and lymphoma ............................................................................................